Search results
Lupus Complications Reduced With Common Diabetes Drug
MedPage Today· 5 days agoPeople with systemic lupus erythematosus (SLE) had lower rates of lupus nephritis, chronic kidney disease, and other complications when they were taking ...
FDA Expands argenx's (ARGX) Vyvgart Label to Treat Rare Disorder
Zacks via Yahoo Finance· 8 hours agoPer argenx (ARGX), the label expansion to Vyvgart Hytrulo makes it the first FDA-approved medication...
CAR-T therapy achieves lupus remission breakthrough
BioPharma-Reporter· 6 days agoThis is the first trial to date to show safe elimination of all autoantibodies in patients with systemic lupus erythematosus (SLE) and lupus nephritis (...
Atara Shareholders Approve Reverse Stock Split
Los Angeles Business Journal· 15 hours agoA reverse stock split by Atara Biotherapeutics Inc. has brought the share price of the Thousand Oaks company back into compliance with Nasdaq rules.
US FDA approves Roche's drug for a chronic blood disorder
Reuters· 3 days ago, opens new tab drug for a chronic blood disorder, the Swiss drugmaker said. The drug crovalimab,...
Is Adicet Bio, Inc. (NASDAQ:ACET) the Best Halal Stock ?
Insider Monkey via Yahoo Finance· 3 days agoWe recently compiled the list of the 7 Best Halal Stocks To Buy Now (Debt Free) according to the...
Multiscale topology classifies cells in subcellular spatial transcriptomics - Nature
Nature· 6 days agoA method for topological automatic cell type classification across subcellular resolution spatial transcriptomic platforms is proposed, resolving cell type information and locating sparsely dispersed cells in human kidney and mouse kidney and brain.
'Unprecedented' CAR-T results for lupus net Insight prize for researchers
FierceBiotech· 4 days agoTwo scientists whose work sparked industry excitement about the prospect of using chimeric antigen...
Q32 Bio (NASDAQ:QTTB) Receives New Coverage from Analysts at Guggenheim
ETF DAILY NEWS· 7 days agoGuggenheim assumed coverage on shares of Q32 Bio (NASDAQ:QTTB – Free Report) in a research report released on Monday, Marketbeat reports. The firm issued a buy rating and a $100.00 target price ...